Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s…
<!-- Name:DistributionId Value:8748298 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:SRNE
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19…
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses…
Sorrento Releases Positive Topline Results from the Phase I Study Completed in…
Topline safety and pharmacokinetic (PK) data from the Phase I single ascending dose (SAD)/multiple ascending dose (MAD) study of STI-1558 in 58 healthy volunteers in Australia are now…
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of…
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored…
Sorrento Announces the Publication in the Nature Journal Scientific Reports the…
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and…
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of…
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections…
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast…
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following:More frequent meetings or written communication with the FDA to discuss the SP-103…
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA)…
STI-1558, an oral SARS-CoV-2 main protease (Mpro) inhibitor, which can block viral replication, is specifically designed as a standalone treatment of COVID-19 without ritonavir as a…
Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G.…
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq:…
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G.…
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and…